Spero Therapeutics Hits 52-Week Low at $1.42 Amid Market Challenges

Spero Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.42 on July 20, 2026. This decline marks a significant downturn for the stock, which has seen a modest one-year performance of 0.7%, contrasting sharply with the S&P 500's gain of 18.21% during the same period. With a market capitalization of USD 135 million, Spero Therapeutics operates within a competitive industry landscape. The company's price-to-earnings (P/E) ratio stands at 14.00, indicating its current valuation relative to earnings. Additionally, Spero Therapeutics has a price-to-book ratio of 2.29, reflecting its market value compared to its book value. The company does not offer a dividend, and its debt-to-equity ratio is reported at -0.65, suggesting a unique financial structure. Furthermore, Spero Therapeutics has achieved a return on equity of 15.96%, highlighting its efficiency in generating profits from shareholders' equity. As the stock navigates these recent developments, its performance metrics will be closely monitored by market participants.